Sermorelin
GHRH Analog (natural sequence)Also known as: GHRH(1-29) · Sermorelin acetate · Geref
The native GHRH 1-29 sequence approved for clinical GH deficiency diagnosis & treatment. The oldest & most clinically validated GH secretagogue.
Typical Dose
200–300 mcg per injection
Route
Subcutaneous injection
Cycle
12–24 weeks
Half-life
~10–12 minutes (shorter than CJC-1295; dose accordingly)
Storage
Reconstituted: 2–8°C, use within 30 days. Lyophilized: room temp or freezer.
Overview
Sermorelin is the first 29 amino acids of endogenous Growth Hormone-Releasing Hormone, the exact natural sequence responsible for triggering GH release from the anterior pituitary. Unlike synthetic GHRH analogs with substitutions for stability (like CJC-1295), Sermorelin is the native sequence & therefore has a short half-life of approximately 10–12 minutes.
Sermorelin has FDA approval for the diagnosis & treatment of growth hormone deficiency in children, & was used extensively in age-related GH decline before being withdrawn from the US market in 2008 for commercial reasons. It remains in use in compounding pharmacy form & is widely studied for adult anti-aging applications.
Because it stimulates pulsatile physiological GH release rather than replacing it, Sermorelin preserves pituitary sensitivity & does not suppress endogenous GH production with standard use. This is a significant advantage over exogenous GH administration.
Quick Start Guide
Reconstitute with 2 mL bacteriostatic water per 3 mg vial.
Inject 200–300 mcg subcutaneously 30 minutes before sleep.
Stack with Ipamorelin or GHRP-2 for synergistic GH pulse amplification.
Research Indications
GH deficiency (children)
Most EffectiveFDA-approved indication. Clinically validated for restoring physiological GH pulsatility in GHD children.
Age-related GH decline (somatopause)
EffectiveAdult clinical studies show measurable IGF-1 increases & improved body composition with Sermorelin treatment in the context of age-related GH decline.
Research Protocols
Anti-aging / body composition
12–24 weeksDose
200–300 mcg + Ipamorelin 200 mcg
Frequency
Once daily pre-sleep
Route
SubQ abdomen
Peptide Interactions
Same complementary GHRH/GHRP mechanism as CJC-1295 + Ipamorelin. Sermorelin is a viable alternative to CJC-1295 (no DAC); the shorter half-life means dose timing is slightly more important.
Both are GHRH analogs — no benefit to stacking them together; pick one.
Side Effects & Safety
Common
- Injection site redness
- Transient flushing
- Water retention (IGF-1 driven)
Uncommon
- Headache
- Dizziness
When to Stop
- Active malignancy
- Signs of allergic reaction
How to Reconstitute
Swab the vial stopper.
Draw 2 mL bacteriostatic water per 3 mg vial.
Inject slowly down the inner wall. Swirl gently.
Refrigerate at 2–8°C.
Dosing math: 2 mL BAC water per 3 mg vial gives 1500 mcg/mL. For 200 mcg dose: draw 0.13 mL.
Quality Indicators
Good — use as normal
- Clear, colorless solution
Acceptable
- Very minor cloudiness clearing immediately
Discard immediately
- Persistent cloudiness
- Discoloration
- Particulate
What to Expect
Week 1–2
GH pulses begin immediately. Improved sleep & recovery are the first reported effects.
Week 3–8
IGF-1 rises, body composition changes begin. Similar arc to Ipamorelin protocols.
Community Insights
Self-reported. Reflects user experience, not clinical outcomes.
Research References
Sermorelin in adult growth hormone deficiency
Journal of Clinical Endocrinology & Metabolism · 1997
Clinical study demonstrating IGF-1 normalization & improved body composition with Sermorelin treatment in adults with GHD.
Verify what you have
Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.
Submit a sample